证券代码：300347 证券简称：泰格医药 公告编码（2025）031 号 杭州泰格医药科技股份有限公司 关于出售参股公司股权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 一、交易背景 2019年12月，经杭州泰格医药科技股份有限公司（以下简称"公司"）董事长审议 批准，公司所属投资平台杭州泰格股权投资合伙企业（有限合伙）（以下简称"泰格股 权"）取得礼新医药科技（上海）有限公司（以下简称"礼新医药"或"标的公司"） 4.762%的股权。经公司董事长审议批准，公司分别于2020年5月和11月签署追加投资认 购协议，通过泰格股权以自有资金分别追加投资1,000万人民币和4,000万人民币认购礼 新医药新发行的2.86%以及2.65%股权。 以上投资事项均不构成关联交易，不构成《上市公司重大资产重组管理办法》规 定的重大资产重组，无需提交董事会审批，公司已履行相应的内部审批程序。 截至本公告披露日，公司通过泰格股权直接持有礼新医药股权比例为3.41%；通过 持有基金等份额穿透后间接持有礼新医药股权比例为4.58%。公司在礼新医药无董事席 位。 二、本次交 ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）030 号 1 大制药"或"买方"）。公司作为礼新医药参股股东，在全面分析创新药市场、标的公司的 核心技术和经营情况后，拟同意标的公司的出售安排，配合其将泰格股权直接持有礼新医 药的全部股权以对价约3,411万美元转让给买方，并签署相关交易文件。 杭州泰格医药科技股份有限公司 第五届董事会第十七次会议决议公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）第五届董事会第十七次会议于2025 年7月17日在杭州市滨江区聚工路19号盛大科技园A座18层会议室举行，本次会议以现场与 通讯表决相结合的方式召开。会议通知已于2025年7月15日以电话、电子邮件方式向全体董 事发出。会议应到董事7人，实到董事7人，本次会议由公司董事长叶小平主持。本次会议 的召开及程序符合有关法律、法规和公司章程的要求，会议合法有效。 经与会董事审议，本次会议以投票表决的方式审议通过如下决议： 一、审议并通过《关于出售参股公司股权的议案》。 2019年12月，经杭州泰 ...

智通财经7月17日电，泰格医药(300347.SZ)公告称，公司通过泰格股权直接持有礼新医药股权比例为 3.41%；通过持有基金等份额穿透后间接持有礼新医药股权比例为4.58%。礼新医药拟将95.09%股权转 让给正大制药投资（北京）集团有限公司。公司拟同意标的公司的出售安排，配合将泰格股权直接持有 的礼新医药全部股权以约3,411万美元转让给买方。本次交易完成后，公司将不再持有礼新医药的股 权。 泰格医药：出售参股公司礼新医药股权 ...

Core Viewpoint - Tiger Medical (300347) announced that its investment platform, Tiger Equity, acquired a 4.762% stake in Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. and made additional investments of 10 million RMB and 40 million RMB to subscribe for newly issued shares of 2.86% and 2.65% respectively [1] Group 1 - As of the announcement date, Tiger Medical directly holds 3.41% of Lixin Pharmaceutical's equity through Tiger Equity, and indirectly holds 4.58% through fund shares [1] - Lixin Pharmaceutical plans to transfer 95.09% of its equity to Chia Tai Pharmaceutical Investment (Beijing) Group Co., Ltd., and Tiger Medical agrees to sell all its holdings for approximately 34.11 million USD [1] - This transaction is expected to enhance cash income, supplement cash flow, and promote the sustainable and healthy development of the company while maximizing shareholder value [1]

Group 1 - The China Securities Hong Kong Stock Connect Medical Theme Index (932069) has seen a strong increase of 2.89%, with notable gains in constituent stocks such as Kangfang Biotech (09926) up 10.16%, BeiGene (06160) up 9.17%, and Kelun-Biotech (06990) up 8.05% [1][2] - The Hong Kong Medical ETF (159366) has risen by 2.00%, marking its third consecutive increase, with the latest price reaching 1.38 HKD, a new high [1][2] - The index reflects the performance of 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology within the Hong Kong Stock Connect framework [6] Group 2 - The 2025 National Basic Medical Insurance and other insurance drug directories have officially started adjustments, with the first addition of innovative drugs to the commercial health insurance directory this year [3] - WuXi AppTec has disclosed a positive half-year performance forecast for 2025, exceeding market expectations, leading to a collective rise in the CXO sector [4] - The AI medical technology sector is transitioning towards multi-modal integration, significantly enhancing the intelligence level in medical scenarios, with AI-assisted diagnosis systems penetrating 89% of top-tier hospitals [4] Group 3 - The medical device and traditional Chinese medicine sectors are expected to see a performance turning point in the second half of 2025, with a focus on new technology directions such as medical devices, AI healthcare, and brain-computer interfaces [5] - The Hong Kong Medical ETF aggregates rare and specialized medical segment leaders from the mainland, focusing on internet healthcare, CXO, and medical devices [5] - As of June 30, 2025, the top ten weighted stocks in the index accounted for 57.7% of the total, including companies like WuXi Biologics (02269) and JD Health (06618) [6]

Group 1 - Hong Kong biopharmaceutical stocks experienced an initial surge, with 康方生物 (09926.HK) rising over 8% [1] - 泰格医药 (03347.HK) increased by more than 4% [1] - 百济神州 (06160.HK) and 复宏汉霖 (02696.HK) both saw nearly 4% gains [1] - 金斯瑞生物科技 (01548.HK) rose by over 3% [1]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in recent months and has a significant allocation in leading healthcare companies [1][3]. - As of July 15, 2025, the latest net value of the fund is 1.7462 yuan, reflecting a growth of 1.28%. The fund's one-month return is 2.18%, six-month return is 18.43%, and year-to-date return is 14.30% [1]. - The fund's top ten stock holdings account for a total of 55.30%, with significant investments in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1]. Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan. The fund is managed by Guo Lan and Zhao Lei [1]. - Guo Lan, the fund manager, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]. - Zhao Lei, also a fund manager, has experience in the pharmaceutical and biotechnology sectors, having worked as a researcher and analyst before joining China Europe Fund Management in 2021 [2].

Summary of Conference Call Records Industry Overview - The global pharmaceutical industry is facing a significant patent cliff, with approximately $180 billion in annual revenue drugs set to lose patent protection between 2027 and 2028, representing nearly 12% of the global market share [3][4][10] - The domestic innovation industry chain is experiencing an increase in orders, particularly among upstream companies such as Baipusais, Bidai Pharmaceutical, and Bai'ao Pharmaceutical [1][5] - The CRO (Contract Research Organization) sector is seeing growth in companies like Zhaoyan New Drug, Yinuosi, and Tigermed, while the CDMO (Contract Development and Manufacturing Organization) sector is highlighted by strong performances from WuXi AppTec, Boteng Co., Tianyu Co., and Pro Pharma [1][5] Key Insights and Arguments - The recovery in the CXO (Contract Research Organization and Contract Development and Manufacturing Organization) sector is driven by increased domestic demand and a resurgence in orders, which is expected to translate into clinical research opportunities within 6 to 12 months [11][12] - The trend of innovation drug out-licensing (BD) is becoming more pronounced, as large pharmaceutical companies seek to diversify their pipelines and manage costs amid pressures from legislation such as the IRA (Inflation Reduction Act) [4][7] - Domestic listed companies have shown an increasing trend in R&D expenses as a percentage of revenue since the second half of last year, indicating a more proactive approach to R&D investment in response to market changes [8][10] Financial Performance and Trends - In the CDMO sector, WuXi AppTec reported a 47% year-on-year increase in orders by the end of last year, while Boteng Co. saw a 30% increase [11][13] - For the first half of 2025, WuXi AppTec's revenue is expected to grow by 21%, with a 44% increase in NON-IFRS net profit, while Boteng Co. is projected to achieve profitability after a turnaround [13] - The structure of R&D expenses in Biotech companies has shifted, with a notable increase in clinical trial costs, reflecting a conservative investment strategy amid market uncertainties [9] Potential Investment Opportunities - Recommended companies in the domestic innovation industry include Yinuosi, Zhaoyan New Drug, and Tigermed, as well as leading CDMO firms like WuXi AppTec and Pro Pharma [16] - The recovery in the domestic innovation industry is expected to create further investment opportunities, particularly as IPOs are being opened up and more companies are preparing to list [14] Additional Considerations - The overall recovery of the innovation industry chain is segmented into phases, with the current transition from phase 1.0 to 2.0 indicating a shift towards increased early-stage project investments by financially robust companies [10] - The competitive landscape of the domestic innovation industry chain should be assessed comprehensively, including comparisons with Indian and other overseas companies to better understand competitive advantages [17]

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase of 0.94% but a one-month return of -0.94% [1] - The fund's three-month return is 16.34%, ranking 306 out of 1238 similar funds, while its year-to-date return is 10.10%, ranking 434 out of 1218 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund is managed by two key managers: Ms. Ge Lan, who has been managing it since its inception, and Ms. Zhao Lei, who took over management on July 4, 2025 [2]

Core Viewpoint - The Hong Kong stock market for the biopharmaceutical sector experienced a significant rebound today, with several companies showing notable gains [1] Group 1: Company Performance - Rongchang Biopharmaceutical (09995.HK) rose over 7% [1] - Junshi Biosciences (01877.HK) increased by more than 4% [1] - Other companies such as Tigermed (03347.HK), Zai Lab (09688.HK), and Innovent Biologics (02696.HK) also saw their stock prices rise [1]